Revenue Breakdown
Composition ()
No data
Revenue Streams
Enovis Corp (ENOV) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is International Reconstructive, accounting for 23.5% of total sales, equivalent to $128.99M. Other significant revenue streams include U.S. Reconstructive and U.S. Bracing & Support. Understanding this composition is critical for investors evaluating how ENOV navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Enovis Corp maintains a gross margin of 52.23%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 2.08%, while the net margin is -104.00%. These profitability ratios, combined with a Return on Equity (ROE) of -51.11%, provide a clear picture of how effectively ENOV converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ENOV competes directly with industry leaders such as CNMD and IRMD. With a market capitalization of $1.22B, it holds a significant position in the sector. When comparing efficiency, ENOV's gross margin of 52.23% stands against CNMD's 58.49% and IRMD's 77.80%. Such benchmarking helps identify whether Enovis Corp is trading at a premium or discount relative to its financial performance.
